Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE study

BMC Geriatrics

Volumn 5, Issue , 2005, Pages

  Yip, Agustín G ^a   Green, Robert C ^a,b   Huyck, Matthew ^a   Cupples, L Adrienne ^b   Farrer, Lindsay A ^a,b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; NONSTEROID ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN E4;

ADULT; AFRICAN AMERICAN; AGED; ALZHEIMER DISEASE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DRUG USE; ETHNOLOGY; FAMILY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; RISK REDUCTION; STATISTICAL SIGNIFICANCE; CLINICAL TRIAL; GENETICS; MIDDLE AGED; MULTICENTER STUDY;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 14544306103     PISSN: 14712318     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-5-2     Document Type: Article

References (22)

1. Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MM, Hofman A: Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? The Rotterdam Study. Neurology 1995, 45:1441-1445.
2. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV: Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000, 54:2066-2071.
3. Broe GA, Grayson DA, Creasey HM, Waite LM, Casey BJ, Bennett HP, Brooks WS, Halliday GM: Anti-inflammatory drugs protect against Alzheimer's disease at low doses. Arch Neurol 2000,57:1586-1591.
4. The Canadian Study of Health and Aging: risk factors for Alzheimer's disease in Canada. Neurology 1994, 44:2073-2080.
5. in 't Veld BA, Launer LJ, Hoes AW, Ott A, Hofman A, Breteler MM, Stricker BH: NSAIDs and incident Alzheimer's disease. The Rotterdam Study. Neurobiol Aging 1998, 19:607-611.
6. Stewart WF, Kawas C, Corrada M, Metter EJ: Risk of Alzheimer's disease and duration of NSAID use. Neurology 1997, 48:626-632.
7. in't Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T, Breteler MM, Stricker BH: Nonsteroidal anti-inflammatory drugs and risk of Alzheimer's disease. N Engl J Med 2001,345:1515-1521.
8. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I: Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 2002, 156:445-453.
9. Zandi PP, Anthony JC, Hayden KM, Mehta K, Mayer L, Breitner JC, Cache County Study Investigators: Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 2002, 59:880-886.
10. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC: Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a cotwin control study. Neurology 1994, 44:227-232.
11. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E: Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998, 73:951-955.
12. Henderson AS, Jorm AF, Christensen H, Jacomb PA, Korten AE: Aspirin, anti-inflammatory drugs and risk of dementia. Int J Geriatr Psychiatry 1997, 12:926-930.
13. Lautenschlager NT, Cupples LA, Rao VS, Auerbach SA, Becker R, Burke J, Chui H, Duara R, Foley EJ, Glatt SL, Green RC, Jones R, Karlinsky H, Kukull WA, Kurz A, Larson EB, Martelli K, Sadovnick AD, Volicer L, Waring SC, Growdon JH, Farrer LA: Risk of dementia among relatives of Alzheimer's disease patients in the MIRAGE study: What is in store for the oldest old? Neurology 1996, 46:641-650.
14. Farrer LA, Cupples LA, Blackburn S, Kiely DK, Auerbach S, Growdon JH, Connor-Lacke L, Karlinsky H, Thibert A, Burke JR: Interrater agreement for diagnosis of Alzheimer disease: the MIRAGE Study. Neurology 1994, 44:652-656.
15. Demissie S, Green RC, Mucci L, Tziavas S, Martelli K, Bang K, Coons L, Bourque S, Buchillon D, Johnson K, Smith T, Sharrow N, Lautenschlager N, Friedland R, Cupples LA, Farrer LA: Reliability of information collected by proxy in family studies of Alzheimer disease. Neuroepidemiology 2001, 20:105-111.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group. Neurology 1984, 34:939-944.
17. Brandt J, Spencer M, Folstein M: The telephone interview for cognitive status. Neuropsychiatr Neuropsychol Behav Neurol 1988,1:111-117.
18. Welsh KA, Breitner JCS, Magruder-Habib KM: Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsychiatr Neuropsychol Behav Neurol 1993,6:103-110.
19. Zeger SL, Liang KY: Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-130.
20. Breitner JC, Wyse BW, Anthony JC, Welsh-Bohmer KA, Steffens DC, Norton MC, Tschanz JT, Plassman BL, Meyer MR, Skoog I, Khachaturian A: APOE-ε4 count predicts age when prevalence of AD increases, then declines: The Cache County Study. Neurology 1999, 53:321-331.
21. Ophir G, Meilin S, Efrati M, Chapman J, Karussis D, Roses A, Michaelson DM: Human apoE3 but not apoE4 rescues impaired astrocyte activation in apoE null mice. Neurobiol Dis 2003,12:56-64.
22. Martin BK, Meinert CL, Breitner JC, ADAPT Research Group: Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials 2002, 23:93-99.